Abstract: A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

Abstract: A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

Abstract: A nucleotide sequence comprising the nucleotide sequence of a virus belonging to the group of autonomous parvoviruses, and at least one effector nucleotide sequence which encodes an effector polypeptide capable of effecting the destruction or the normalization of cancer cells or cells infected by virus, bacteria, or intra-cellular infectious parasites.

Abstract: Compound useful particularly for the treatment by targetted radiotherapy or imaging of cancer, characterized in that the compound is comprised of a molecule susceptible of fixing itself or passing close to the DNA of the target cells, said molecule being radiolabelled with iodine 123. The invention also relates to new ligands specific of steroid hormone receivers useful for the targetted therapy or imaging particularly of cancer and presenting a structural base skeleton having the formula (I). According to the invention these ligands comprise particularly a) a hydroxyl or ketone function in position C.sub.3 ; b) a .beta. chloromethyl function on position C.sub.11 ; c) an .alpha. methyl or vinyl function on position C.sub.17 and d) a substituted radioactive iodine on an alkyl or alkenyl group attached to the skeleton, particularly methyl or vinyl.

Abstract: The present invention relates to specific ligands for estrogen or progestagen steroid hormone receptors which have the formula ##STR1## in which X denotes a vinyl group substituted by a radioactive or nonradioactive halogen on the double bond according to a Z isomerism, andY denotes either a hydroxyl group, in which case the ring to which it is attached is an aromatic ring, or a ketone functional group, in which case it is conjugated with a double bond at C.sub.4 -C.sub.5.An application of the ligands according to the invention is the targeted therapy and/or medical imagery, especially of cancer. However, these ligands can also be employed in the quantitative determination of said hormone receptors.However, the labeled ligands according to the invention are of very particular interest in the case of the targeted radiotherapy of cancer.